Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: Comparison with tissue plasminogen activator

Experimental Neurology

Volumn 204, Issue 1, 2007, Pages 138-146

  Furuichi, Yasuhisa ^a   Maeda, Masashi ^a   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a   Yanagihara, Takehiko ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b Osaka Neurological Research Institute   (Japan)

Author keywords

FK506; Focal cerebral ischemia; Nonhuman primate; Therapeutic time window; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION SIZE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RECANALIZATION; STROKE;

ANIMALS; BRAIN; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; NERVOUS SYSTEM; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS; TACROLIMUS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33847360523     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.10.003     Document Type: Article

References (34)

1. Alexandrov A.V., and Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59 (2002) 862-867
2. Barone F.C., and Feuerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 19 (1999) 819-834
3. Bochelen D., Rudin M., and Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J. Pharmacol. Exp. Ther. 288 (1999) 653-659
4. Chen Z.L., and Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91 (1997) 917-925
5. Clark W.M., Madden K.P., Lyden P.D., and Zivin J.A. Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 22 (1991) 872-876
6. Dietrich W.D., Watson B.D., Busto R., Ginsberg M.D., and Bethea J.R. Photochemically induced cerebral infarction: I. Early microvascular alterations. Acta Neuropathol. (Berl.) 72 (1987) 315-325
7. Furuichi Y., Katsuta K., Maeda M., Ueyama N., Moriguchi A., Matsuoka N., Goto T., and Yanagihara T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 965 (2003) 137-145
8. Furuichi Y., Maeda M., Moriguchi A., Sawamoto T., Kawamura A., Matsuoka N., Mutoh S., and Yanagihara T. Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J. Cereb. Blood Flow Metab. 23 (2003) 1183-1194
9. Furuichi Y., Noto T., Li J.Y., Oku T., Ishiye M., Moriguchi A., Aramori I., Matsuoka N., Mutoh S., and Yanagihara T. Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res. 1014 (2004) 120-130
10. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G., Schneider D., Diez-Tejedor E., and Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352 (1998) 1245-1251
11. Herr I., Martin-Villalba A., Kurz E., Roncaioli P., Schenkel J., Cifone M.G., and Debatin K.M. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. Brain Res. 826 (1999) 210-219
12. Kawai H., Umemura K., and Nakashima M. Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn. J. Pharmacol. 69 (1995) 143-148
13. Lijnen H.R., Maraafino Jr. B.J., and Collen D. In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species. Thromb. Haemost. 52 (1984) 308-310
14. Maeda M., Furuichi Y., Ueyama N., Moriguchi A., Satoh N., Matsuoka N., Goto T., and Yanagihara T. A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window. J. Cereb. Blood Flow Metab. 22 (2002) 1205-1211
15. Maeda M., Moriguchi A., Mihara K., Aoki T., Takamatsu H., Matsuoka N., Mutoh S., and Goto T. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator. J. Cereb. Blood Flow Metab. 25 (2005) 108-118
16. Maeda M., Takamatsu H., Furuichi Y., Noda A., Awaga Y., Tatsumi M., Yamamoto M., Ichise R., Nishimura S., and Matsuoka N. Characterization of a novel thrombotic middle cerebral artery occlusion model in monkeys that exhibits progressive hypoperfusion and robust cortical infarction. J. Neurosci. Methods 146 (2005) 106-115
17. Marler J.R., Tilley B.C., Lu M., Brott T.G., Lyden P.C., Grotta J.C., Broderick J.P., Levine S.R., Frankel M.P., Horowitz S.H., Haley Jr. E.C., Lewandowski C.A., and Kwiatkowski TP. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 55 (2000) 1649-1655
18. Matsuno H., Uematsu T., Umemura K., Takiguchi Y., Wada K., and Nakashima M. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br. J. Pharmacol. 106 (1992) 533-538
19. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E.T., Vivien D., and Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7 (2001) 59-64
20. Rosen G.D., and Harry J.D. Brain volume estimation from serial section measurements: a comparison of methodologies. J. Neurosci. Methods 35 (1990) 115-124
21. Sharkey J., and Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 371 (1994) 336-339
22. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
23. STAIR-II. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32 (2001) 1598-1606
24. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333 (1995) 1581-1587
25. Tsujikawa A., Ogura Y., Hiroshiba N., Miyamoto K., Kiryu J., and Honda Y. Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. Stroke 29 (1998) 1431-1437
26. Umemura K., Wada K., Uematsu T., and Nakashima M. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 24 (1993) 1077-1081
27. Umemura K., Wada K., Uematsu T., Mizuno A., and Nakashima M. Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F, in the rat middle cerebral artery occlusion model. Eur. J. Pharmacol. 251 (1994) 69-74
28. Umemura K., Ishiye M., Kosuge K., and Nakashima M. Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model. Eur. J. Pharmacol. 275 (1995) 17-21
29. Wakita H., Tomimoto H., Akiguchi I., and Kimura J. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. Brain Res. 792 (1998) 105-113
30. Wang Y.F., Tsirka S.E., Strickland S., Stieg P.E., Soriano S.G., and Lipton S.A. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4 (1998) 228-231
31. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284 (1999) 339-343
32. Watson B.D., Dietrich W.D., Busto R., Wachtel M.S., and Ginsberg M.D. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann. Neurol. 17 (1985) 497-504
33. Yagita Y., Kitagawa K., Matsushita K., Taguchi A., Mabuchi T., Ohtsuki T., Yanagihara T., and Matsumoto M. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sci. 59 (1996) 1643-1650
34. Zhang R.L., Zhang Z.G., and Chopp M. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology 52 (1999) 273-279